Results
FOR IMMEDIATE RELEASE
Boston Scientific announces results for third quarter 2026
Marlborough, Mass.
6(October 28, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational 1 and organic 2 basis, all compared to the prior year period.
8The company reported GAAP net income attributable to Boston Scientific common stockholders of $582 million or $0.40 per share (EPS), compared to $755 million or $0.51 per share a year ago, and achieved adjusted 3 EPS of $0.73 for the period, compared to $0.75 a year ago.
"This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
"As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation."
Third quarter financial results and recent developments:
7Reported net sales of $5.138 billion, representing an increase of 1.5 percent on a reported, operational and organic basis, all compared to the prior year period.
Reported GAAP net income attributable to Boston Scientific common stockholders of $0.40 per share, and achieved adjusted EPS of $0.73 per share.
Achieved the following net sales growth in each reportable segment, compared to the prior year period:
MedSurg: 0.6 percent reported, 0.7 percent operational and organic
Cardiovascular: 1.9 percent reported, operational and organic
Achieved the following net sales growth/(decline) in each region, compared to the prior year period:
United States (U.S.): 0.5 percent reported and operational
Europe, Middle East and Africa (EMEA): 4.4 percent reported and 6.1 percent operational
Asia-Pacific (APAC): (0.6) percent reported and (1.1) percent operational
Latin America and Canada (LACA): 16.0 percent reported and 10.5 percent operational
Commenced enrollment in the Elite AF clinical trial to evaluate the safety and effectiveness of the next-generation WATCHMAN Elite™ Left Atrial Appendage Closure Device in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy to reduce their risk of stroke and who have a rationale to seek a non-pharmacologic alternative.
2Received U.S. Food and Drug Administration (FDA) 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem, including the Navigator™ Flex Ureteral Access Sheath Set , designed to enable the use of suction to remove kidney stone debris, and the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with temperature sensing , designed to display real-time fluid temperature alongside ureteroscopy video for procedural monitoring.
1Received U.S. FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat patients with severely calcified peripheral artery disease both above and below the knee.
Recognized the American Medical Association's assignment of Category I Current Procedural Terminology (CPT®) codes for renal denervation devices, such as the investigational TIVUS™ Renal Denervation
System, and implantable tibial nerve stimulation (ITNS) devices, including the eCoin® ITNS System , effective January 2028.
Entered into a strategic collaboration with Heartflow, Inc. (Nasdaq: HTFL) to advance AI-powered, computed tomography (CT)-guided planning for percutaneous coronary intervention (PCI) procedures and explore integration of Heartflow's PCI Navigator pre-procedural planning tool and the AVVIGO™+ Multi-Modality Guidance System .
Operational net sales growth excludes the impact of foreign currency fluctuations.
Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.
Net sales for the third quarter by business and region:
Guidance for Full Year and Fourth Quarter 2026
5The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis.
Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
The company now estimates adjusted EPS, excluding certain charges (credits), of $3.16 to $3.18.
4The company estimates net sales to decline in the fourth quarter of 2026, versus the prior year period, by approximately (3.0) to (1.0) percent on a reported and organic basis.
Fourth quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and
divestitures for which there are less than a full period of comparable net sales.
The company estimates adjusted EPS, excluding certain charges (credits), of $0.77 to $0.79.
The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges.
The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world.
3As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.
Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
Learn more at www.bostonscientific.com and follow us on LinkedIn .
These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.
Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events, including the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our prior and new restructuring programs; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve sustainability goals; and future business decisions made by us and our competitors.
New risks and uncertainties may arise from time to time and are difficult to predict.
All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A.
Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A.
Risk Factors in Quarterly
Reports on Form 10-Q we have filed or will file hereafter.
Note : Amounts reported in millions within this press release are computed based on the amounts in thousands.
As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding.
Certain columns and rows within tables may not add due to the use of rounded numbers.
Percentages presented are calculated from the underlying unrounded amounts.
Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
CONTACT:
Media:Chanel HastingsInvestors:Lauren Tengler
508-382-0288 (office)508-683-4479 (office)
Media RelationsInvestor Relations
Boston Scientific CorporationBoston Scientific Corporation
BOSTON SCIENTIFIC CORPORATION
16 boilerplate lines (safe-harbor disclaimer, contacts, call details) are set aside.